T. Rowe Price Investment Management’s Utah Medical Products UTMD Stock Holding History

T. Rowe Price Investment Management’s Portfolio UTMD Stock Details UTMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-269,166	Closed	-$22.7M	–	659
2023 Q4	$22.7M	Sell	269,166 -60,146	-18%	-$4.99M	0.01%	473
2023 Q3	$28.3M	Sell	329,312 -11,806	-3%	-$1.09M	0.02%	442
2023 Q2	$31.8M	Sell	341,118 -8,722	-2%	-$822K	0.02%	433
2023 Q1	$33.2M	Buy	349,840 +7,924	+2%	+$728K	0.02%	418
2022 Q4	$34.4M	Sell	341,916 -271	-0.1%	-$24.7K	0.03%	402
2022 Q3	$29.2M	Buy	+342,187	New	+$30.2M	0.02%	415

Other funds holding UTMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

T. Rowe Price Investment Management's UTMD Position: Q1 2024 in Review

T. Rowe Price Investment Management sold out of Utah Medical Products (UTMD) in Q1 2024, closing a stake of 269,166 shares — an estimated $22.7M sold.

T. Rowe Price Investment Management first reported a position in UTMD in Q3 2022 and held it in 6 quarters. The position peaked at $34.4M in Q4 2022. 100 funds tracked by Wall St. Rank hold UTMD as of Q1 2024.

T. Rowe Price Investment Management reported no remaining Utah Medical Products position as of Q1 2024 after selling out during the quarter.
T. Rowe Price Investment Management sold 269,166 Utah Medical Products shares in Q1 2024, an estimated $22.7M.
T. Rowe Price Investment Management first reported a position in Utah Medical Products in Q3 2022 and held it in 6 quarters.
T. Rowe Price Investment Management's Utah Medical Products position peaked at $34.4M in Q4 2022.
100 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2024.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2024, filed 15 May 2024.